Novel tools to assist neoepitope targeting in personalized cancer immunotherapy

Sunil Kumar Saini*, Nicolle Rekers, Sine Reker Hadrup

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

Current cancer immunotherapy approaches utilize the remarkable surveillance capacity of the human immune system, which is capable of recognizing and eliminating cancer cells based on identification of tumor-associated antigens arising as a consequence of the transformation process. Among these, mutational-derived neoepitopes have proved to be powerful targets for tumor elimination and mutational load has been shown to correlate with the clinical response to treatment with checkpoint inhibitors in many different tumor types. This suggests a crucial role for neoepitope recognition in T-cell-mediated tumor eradication. Consequently, strategies to further boost neoepitope recognition, through vaccination or adoptive cell transfer, has received substantial interest. Although such strategies have enormous potential, there are also considerable challenges associated with these approaches. In the present review, we will focus on how novel technological developments can facilitate and improve feasibility and efficacy in neoepitope targeting.
Original languageEnglish
JournalAnnals of Oncology
Volume28
Issue numbersuppl_12
Pages (from-to)3-10
ISSN0923-7534
DOIs
Publication statusPublished - 2017

Keywords

  • Cancer immunotherapy
  • Combination therapy
  • Neoantigen
  • T-cells detection
  • Biomarkers
  • Personalised vaccine

Cite this

@article{e5b6658c3af141e08a79af18d530e894,
title = "Novel tools to assist neoepitope targeting in personalized cancer immunotherapy",
abstract = "Current cancer immunotherapy approaches utilize the remarkable surveillance capacity of the human immune system, which is capable of recognizing and eliminating cancer cells based on identification of tumor-associated antigens arising as a consequence of the transformation process. Among these, mutational-derived neoepitopes have proved to be powerful targets for tumor elimination and mutational load has been shown to correlate with the clinical response to treatment with checkpoint inhibitors in many different tumor types. This suggests a crucial role for neoepitope recognition in T-cell-mediated tumor eradication. Consequently, strategies to further boost neoepitope recognition, through vaccination or adoptive cell transfer, has received substantial interest. Although such strategies have enormous potential, there are also considerable challenges associated with these approaches. In the present review, we will focus on how novel technological developments can facilitate and improve feasibility and efficacy in neoepitope targeting.",
keywords = "Cancer immunotherapy, Combination therapy, Neoantigen, T-cells detection, Biomarkers, Personalised vaccine",
author = "Saini, {Sunil Kumar} and Nicolle Rekers and Hadrup, {Sine Reker}",
year = "2017",
doi = "10.1093/annonc/mdx544",
language = "English",
volume = "28",
pages = "3--10",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "suppl_12",

}

Novel tools to assist neoepitope targeting in personalized cancer immunotherapy. / Saini, Sunil Kumar; Rekers, Nicolle; Hadrup, Sine Reker.

In: Annals of Oncology, Vol. 28, No. suppl_12, 2017, p. 3-10.

Research output: Contribution to journalJournal articleResearchpeer-review

TY - JOUR

T1 - Novel tools to assist neoepitope targeting in personalized cancer immunotherapy

AU - Saini, Sunil Kumar

AU - Rekers, Nicolle

AU - Hadrup, Sine Reker

PY - 2017

Y1 - 2017

N2 - Current cancer immunotherapy approaches utilize the remarkable surveillance capacity of the human immune system, which is capable of recognizing and eliminating cancer cells based on identification of tumor-associated antigens arising as a consequence of the transformation process. Among these, mutational-derived neoepitopes have proved to be powerful targets for tumor elimination and mutational load has been shown to correlate with the clinical response to treatment with checkpoint inhibitors in many different tumor types. This suggests a crucial role for neoepitope recognition in T-cell-mediated tumor eradication. Consequently, strategies to further boost neoepitope recognition, through vaccination or adoptive cell transfer, has received substantial interest. Although such strategies have enormous potential, there are also considerable challenges associated with these approaches. In the present review, we will focus on how novel technological developments can facilitate and improve feasibility and efficacy in neoepitope targeting.

AB - Current cancer immunotherapy approaches utilize the remarkable surveillance capacity of the human immune system, which is capable of recognizing and eliminating cancer cells based on identification of tumor-associated antigens arising as a consequence of the transformation process. Among these, mutational-derived neoepitopes have proved to be powerful targets for tumor elimination and mutational load has been shown to correlate with the clinical response to treatment with checkpoint inhibitors in many different tumor types. This suggests a crucial role for neoepitope recognition in T-cell-mediated tumor eradication. Consequently, strategies to further boost neoepitope recognition, through vaccination or adoptive cell transfer, has received substantial interest. Although such strategies have enormous potential, there are also considerable challenges associated with these approaches. In the present review, we will focus on how novel technological developments can facilitate and improve feasibility and efficacy in neoepitope targeting.

KW - Cancer immunotherapy

KW - Combination therapy

KW - Neoantigen

KW - T-cells detection

KW - Biomarkers

KW - Personalised vaccine

U2 - 10.1093/annonc/mdx544

DO - 10.1093/annonc/mdx544

M3 - Journal article

VL - 28

SP - 3

EP - 10

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - suppl_12

ER -